Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF) (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $241000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 4.78% to $241000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $921000.0 through Dec 2025, down 2.23% year-over-year, with the annual reading at $921000.0 for FY2025, 2.23% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $241000.0 at Centessa Pharmaceuticals, up from $237000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $246000.0 in Q4 2023, with the low at $28000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $175250.0, with a median of $233000.0 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 640.62% in 2023, then dropped 9.58% in 2025.
  • Over 4 years, Depreciation & Amortization (CF) stood at $36000.0 in 2022, then surged by 583.33% to $246000.0 in 2023, then fell by 6.5% to $230000.0 in 2024, then rose by 4.78% to $241000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $241000.0, $237000.0, and $226000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.